# DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)

> **NCT07274462** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Martin** · enrollment: 20 (estimated)

## Conditions studied

- Microvascular Inflammation - MVI in Kindey Transplant Recipients

## Interventions

- **DRUG:** DARATUMUMAB (DARZALEX®)
- **OTHER:** Observation (Standard Care)

## Key facts

- **NCT ID:** NCT07274462
- **Lead sponsor:** University Hospital, Martin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-09-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07274462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07274462, "DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07274462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*